2-[8-[(4-carbamimidoylphenyl)carbamoyl]-3-oxo-4-(2-phenylethyl)-2,5-dihydro-1H-1,4-benzodiazepin-2-yl]acetic acid;dihydrochloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[8-[(4-carbamimidoylphenyl)carbamoyl]-3-oxo-4-(2-phenylethyl)-2,5-dihydro-1H-1,4-benzodiazepin-2-yl]acetic acid;dihydrochloride
• 化学式: C27H29Cl2N5O4
• 分子量: 558.5
• InChiKey: CDJRCEHUVXYLHC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.91
• 重原子数：
  38
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  149
• 氢给体数：
  7
• 氢受体数：
  6

文献信息

• Combination therapy for inhibition of platelet aggregation
  申请人：Porter Stephen R.

  公开号：US20070082840A1

  公开（公告）日：2007-04-12

  The invention features methods for preventing platelet activation and aggregation and for treating individuals suffering from conditions or undergoing procedures that may result in unwanted platelet aggregation. The methods are based on the intravenous, subcutaneous, or transdermal administration of a platelet activation or aggregation inhibitor, e.g., xemilofiban, followed by oral administration of the same or a different platelet activation or aggregation inhibitor. The treatment may commence prior to a medical or surgical procedure or after the outbreak of an adverse medical condition, either of which results in the activation of platelets that may lead to thrombus formation, and may continue thereafter.
• COMBINATION THERAPY FOR INHIBITION OF PLATELET AGGREGATION
  申请人：PORTER R. Stephen

  公开号：US20100041587A1

  公开（公告）日：2010-02-18

  The invention features methods for preventing platelet activation and aggregation and for treating individuals suffering from conditions or undergoing procedures that may result in unwanted platelet aggregation. The methods are based on the intravenous, subcutaneous, or transdermal administration of a platelet activation or aggregation inhibitor, e.g., xemilofiban, followed by oral administration of the same or a different platelet activation or aggregation inhibitor. The treatment may commence prior to a medical or surgical procedure or after the outbreak of an adverse medical condition, either of which results in the activation of platelets that may lead to thrombus formation, and may continue thereafter.
• [EN] COMBINATION THERAPY FOR INHIBITION OF PLATELET AGGREGATION<br/>[FR] POLYTHERAPIE BLOQUANT L'AGREGATION PLAQUETTAIRE
  申请人：VDDI PHARMACEUTICALS

  公开号：WO2005087266A1

  公开（公告）日：2005-09-22

  The invention features methods for preventing platelet activation and aggregation and for treating individuals suffering from conditions or undergoing procedures that may result in unwanted platelet aggregation. The methods are based on the intravenous, subcutaneous, or transdermal administration of a platelet activation or aggregation inhibitor, e.g., xemilofiban, followed by oral administration of the same or a different platelet activation or aggregation inhibitor. The treatment may commence prior to a medical or surgical procedure or after the outbreak of an adverse medical condition, either of which results in the activation of platelets that may lead to thrombus formation, and may continue thereafter.